Conclusion
Patients with intracranial PNET should be managed as per EWSR1 gene
rearrangement report. If rearrangement is detected, the treatment will
be planned on the lines of peripheral PNET / Ewing’s sarcoma, including
focal RT and chemotherapy as per EFT protocol. If rearrangement is not
detected, the line of management will be as per embryonal tumor, i.e.,
like high-risk medulloblastoma, necessitating CSI with tumor bed boost,
with concurrent chemotherapy, followed by adjuvant chemotherapy.
Vincristine can be used in concurrent setting instead of carboplatin.
References :
1. Picard D, Miller S, Hawkins CE, Bouffet E, Rogers HA, Chan TSY, et
al. Markers of survival and metastatic potential in childhood CNS
primitive neuro-ectodermal brain tumours: an integrative genomic
analysis. Lancet Oncol. 2012 Aug;13(8):838–48. 2. Ostrom QT, Cioffi G,
Gittleman H, Patil N, Waite K, Kruchko C, et al. CBTRUS Statistical
Report: Primary Brain and Other Central Nervous System Tumors Diagnosed
in the United States in 2012-2016. Neuro-Oncol. 2019 Nov 1;21(Suppl
5):v1–100. 3. Kovar H. Ewing’s sarcoma and peripheral primitive
neuroectodermal tumors after their genetic union. Curr Opin Oncol. 1998
Jul;10(4):334–42. 4. McNeil DE, Coté TR, Clegg L, Rorke LB. Incidence
and trends in pediatric malignancies medulloblastoma/primitive
neuroectodermal tumor: A SEER update. Med Pediatr Oncol.
2002;39(3):190–4. 5. Chen J, Jiang Q, Zhang Y, Yu Y, Zheng Y, Chen J,
et al. Clinical Features and Long-Term Outcome of Primary Intracranial
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumors: 14 Cases from
a Single Institution. World Neurosurg. 2019 Feb;122:e1606–14. 6.
Primary Intracranial pPNET/Ewing Sarcoma: Diagnosis, Management, and
Prognostic Factors Dilemma–A Systematic Review of the Literature. World
Neurosurg. 2018 Jul 1;115:346–56. 7. Folpe AL, Hill CE, Parham DM,
O’Shea PA, Weiss SW. Immunohistochemical detection of FLI-1 protein
expression: a study of 132 round cell tumors with emphasis on
CD99-positive mimics of Ewing’s sarcoma/primitive neuroectodermal tumor.
Am J Surg Pathol. 2000 Dec;24(12):1657–62. 8. VandenHeuvel KA, Al-Rohil
RN, Stevenson ME, Qian J, Gross NL, McNall-Knapp R, et al. Primary
intracranial Ewing’s sarcoma with unusual features. Int J Clin Exp
Pathol. 2015 Jan 1;8(1):260–74. 9. Bridge RS, Rajaram V, Dehner LP,
Pfeifer JD, Perry A. Molecular diagnosis of Ewing sarcoma/primitive
neuroectodermal tumor in routinely processed tissue: a comparison of two
FISH strategies and RT-PCR in malignant round cell tumors. Mod Pathol
Off J U S Can Acad Pathol Inc. 2006 Jan;19(1):1–8. 10. Rorke LB. The
cerebellar medulloblastoma and its relationship to primitive
neuroectodermal tumors. J Neuropathol Exp Neurol. 1983 Jan;42(1):1–15.
11. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin
ME, et al. Prediction of central nervous system embryonal tumour outcome
based on gene expression. Nature. 2002 Jan 24;415(6870):436–42. 12.
Sturm D, Orr BA, Toprak UH, Hovestadt V, Jones DTW, Capper D, et al. New
Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs.
Cell. 2016 Feb 25;164(5):1060–72. 13. Louis DN, Perry A, Reifenberger
G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016
World Health Organization Classification of Tumors of the Central
Nervous System: a summary. Acta Neuropathol (Berl). 2016
Jun;131(6):803–20. 14. Louis DN, Perry A, Wesseling P, Brat DJ, Cree
IA, Figarella-Branger D, et al. The 2021 WHO Classification of Tumors of
the Central Nervous System: a summary. Neuro-Oncol. 2021 Aug
1;23(8):1231–51. 15. Dai AI, Backstrom JW, Burger PC, Duffner PK.
Supratentorial primitive neuroectodermal tumors of infancy: clinical and
radiologic findings. Pediatr Neurol. 2003 Nov;29(5):430–4. 16. Miller
S, Rogers HA, Lyon P, Rand V, Adamowicz-Brice M, Clifford SC, et al.
Genome-wide molecular characterization of central nervous system
primitive neuroectodermal tumor and pineoblastoma. Neuro-Oncol. 2011
Aug;13(8):866–79. 17. Cohen BH, Zeltzer PM, Boyett JM, Geyer JR, Allen
JC, Finlay JL, et al. Prognostic factors and treatment results for
supratentorial primitive neuroectodermal tumors in children using
radiation and chemotherapy: A Childrens Cancer Group randomized trial. J
Clin Oncol. 1995 Jul;13(7):1687–96. 18. Timmermann B, Kortmann RD, Kühl
J, Meisner C, Dieckmann K, Pietsch T, et al. Role of radiotherapy in the
treatment of supratentorial primitive neuroectodermal tumors in
childhood: results of the prospective German brain tumor trials HIT
88/89 and 91. J Clin Oncol Off J Am Soc Clin Oncol. 2002 Feb
1;20(3):842–9. 19. Packer RJ, Macdonald T, Vezina G, Keating R, Santi
M. Medulloblastoma and primitive neuroectodermal tumors. Handb Clin
Neurol. 2012;105:529–48. 20. Reddy AT, Janss AJ, Phillips PC, Weiss HL,
Packer RJ. Outcome for children with supratentorial primitive
neuroectodermal tumors treated with surgery, radiation, and
chemotherapy. Cancer. 2000 May 1;88(9):2189–93. 21. De Braganca KC,
Packer RJ. Treatment Options for Medulloblastoma and CNS Primitive
Neuroectodermal Tumor (PNET). Curr Treat Options Neurol. 2013 Oct
1;15(5):593–606. 22. Ho CY, VandenBussche CJ, Huppman AR, Chaudhry R,
Ali SZ. Cytomorphologic and clinicoradiologic analysis of primary
nonhematologic central nervous system tumors with positive cerebrospinal
fluid. Cancer Cytopathol. 2015;123(2):123–35. 23. Stensvold E, Krossnes
BK, Lundar T, Due-Tønnessen BJ, Frič R, Due-Tønnessen P, et al. Outcome
for children treated for medulloblastoma and supratentorial primitive
neuroectodermal tumor (CNS-PNET) – a retrospective analysis spanning 40
years of treatment. Acta Oncol. 2017 Jun 3;56(5):698–705. 24. Rana K,
Wadhwa V, Bhargava EK, Batra V, Mandal S. Ewing’s Sarcoma Multifocal
Metastases to Temporal and Occipital Bone: A Rare Presentation. J Clin
Diagn Res JCDR. 2015 Jun;9(6):MD04–5. 25. Parasuraman S, Langston J,
Rao BN, Poquette CA, Jenkins JJ, Merchant T, et al. Brain metastases in
pediatric Ewing sarcoma and rhabdomyosarcoma: the St. Jude Children’s
Research Hospital experience. J Pediatr Hematol Oncol.
1999;21(5):370–7. 26. Koç ZP, Kara PÖ, Dağtekin A. Detection of unknown
primary tumor in patients presented with brain metastasis by F-18
fluorodeoxyglucose positron emission tomography/computed tomography. CNS
Oncol. 2018 Apr 30;7(2):CNS12. 27. Hueser CN, Nguyen NC, Osman M,
Havlioglu N, Patel AJ. Extrapulmonary small cell sarcinoma: involvement
of the brain without evidence of extracranial malignancy by serial
PET/CT scans. World J Surg Oncol. 2008 Sep 25;6(1):102. 28. Albright AL,
Wisoff JH, Zeltzer PM, Boyett JM, Rorke LB, Stanley P. Effects of
medulloblastoma resections on outcome in children: a report from the
Children’s Cancer Group. Neurosurgery. 1996 Feb;38(2):265–71. 29. Hwang
EI, Kool M, Burger PC, Capper D, Chavez L, Brabetz S, et al. Extensive
Molecular and Clinical Heterogeneity in Patients with Histologically
Diagnosed CNS-PNET Treated as a Single Entity: A Report from the
Children’s Oncology Group Randomized ACNS0332 Trial. J Clin Oncol. 2018
Dec 1;36(34):3388–95. 30. Biswas S, Burke A, Cherian S, Williams D,
Nicholson J, Horan G, et al. Non-pineal supratentorial primitive
neuro-ectodermal tumors (sPNET) in teenagers and young adults: Time to
reconsider cisplatin based chemotherapy after cranio-spinal irradiation?
Pediatr Blood Cancer. 2009 Jul;52(7):796–803. 31. Timmermann B,
Kortmann RD, Kühl J, Rutkowski S, Meisner C, Pietsch T, et al. Role of
radiotherapy in supratentorial primitive neuroectodermal tumor in young
children: results of the German HIT-SKK87 and HIT-SKK92 trials. J Clin
Oncol Off J Am Soc Clin Oncol. 2006 Apr 1;24(10):1554–60. 32. Fangusaro
J, Finlay J, Sposto R, Ji L, Saly M, Zacharoulis S, et al. Intensive
chemotherapy followed by consolidative myeloablative chemotherapy with
autologous hematopoietic cell rescue (AuHCR) in young children with
newly diagnosed supratentorial primitive neuroectodermal tumors
(sPNETs): Report of the Head Start I and II experience. Pediatr Blood
Cancer. 2008;50(2):312–8. 33. Massimino M, Gandola L, Biassoni V,
Spreafico F, Schiavello E, Poggi G, et al. Evolving of therapeutic
strategies for CNS-PNET. Pediatr Blood Cancer. 2013;60(12):2031–5. 34.
Chintagumpala M, Hassall T, Palmer S, Ashley D, Wallace D, Kasow K, et
al. A pilot study of risk-adapted radiotherapy and chemotherapy in
patients with supratentorial PNET. Neuro-Oncol. 2009 Feb 1;11(1):33–40.
Figures :